+11.4%
NEE vs MRNA
+945.0%
-933.6%
-21.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.9% | +13.1% | -8.2% | +4.9% |
| 7D | +9.2% | +20.6% | -11.5% | +9.2% |
| 30D | +16.0% | +27.1% | -11.2% | +16.0% |
| 3M | +2.2% | +353.4% | -351.2% | +2.0% |
| 6M | -6.0% | +446.3% | -452.3% | -6.5% |
| YTD | +12.6% | +776.2% | -763.6% | +9.5% |
| 1Y | +11.4% | +987.9% | -976.5% | +4.8% |
| All | +11.4% | +945.0% | -933.6% | +4.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling